Want to see PEN full AI Analyst Report?

Penumbra (PEN) Earnings Dates, Call Summary & Reports

479 Followers

Earnings Data

Report Date

Aug 04, 2026

After Close (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

1.16

Last Year’s EPS

0.86

Same Quarter Last Year

Analyst Consensus

Hold

Based on 5 Analysts Ratings

Earnings Call Summary

Q3 2025

Earnings Call Date:Nov 05, 2025|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call reflected a strong performance with significant revenue growth, particularly in the VTE and embolization segments, and positive developments in clinical trials, offset by some challenges in international markets and increased operational costs.

Company Guidance

During Penumbra's third-quarter 2025 conference call, the company reported total revenue of $354.7 million, marking a 17.8% year-over-year growth on a reported basis and 16.9% in constant currency. U.S. revenue reached $275 million, a 21.5% increase compared to the previous year. Specifically, U.S. thrombectomy sales rose by 18.5% to $192 million, while the VTE franchise led corporate growth with a 34% rise. Meanwhile, U.S. embolization and access revenue soared by 29.2% to $83 million. International revenue was $79.7 million, reflecting a 6.6% year-over-year increase. The company's gross margin expanded by 130 basis points to 67.8%, and operating income stood at $48.8 million, or 13.8% of revenue. Penumbra's guidance for the year was raised to $1.375 billion to $1.380 billion in revenue, with anticipated U.S. thrombectomy growth of 20% to 21% for 2025. The company remains focused on expanding its market presence, particularly through innovative products like the Lightning Bolt 16 and Lightning Flash 3.0, which have received FDA clearance.

Strong Revenue Growth

Total revenue reached $354.7 million, showing a year-over-year growth of 17.8% on a reported basis and 16.9% in constant currency. U.S. revenue grew by 21.5% to $275 million.

VTE Franchise Leading Growth

The VTE franchise delivered a 34% year-over-year growth, driving overall corporate growth.

Embolization and Access Revenue Surge

U.S. embolization and access revenue increased by 29.2% year-over-year to $83 million.

Gross Margin Expansion

Gross margin improved to 67.8%, up 130 basis points from the previous year, with expectations to reach over 70% by the end of 2026.

Positive Feedback for STORM-PE Trial

STORM-PE trial results showed CAVT superior in reducing right heart strain in PE patients with a favorable safety profile, receiving positive feedback from the medical community.

Raising Revenue Guidance

The company raised its revenue guidance for the year to $1.375 billion to $1.380 billion.

Penumbra (PEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PEN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 04, 2026	2026 (Q2)	1.16 / -	0.86	―	―	―
May 06, 2026	2026 (Q1)	1.04 / 0.82	0.83	-1.20% (-0.01)	―	―
Feb 25, 2026	2025 (Q4)	1.11 / 1.18	0.97	21.65% (+0.21)	―	―
Nov 05, 2025	2025 (Q3)	0.93 / 0.97	0.85	14.12% (+0.12)	―
Jul 29, 2025	2025 (Q2)	0.82 / 0.86	0.64	34.37% (+0.22)	―
Apr 23, 2025	2025 (Q1)	0.67 / 0.83	0.41	102.44% (+0.42)	―
Feb 18, 2025	2024 (Q4)	0.90 / 0.97	0.76	27.63% (+0.21)	―
Oct 30, 2024	2024 (Q3)	0.69 / 0.85	0.67	26.87% (+0.18)	―
Jul 30, 2024	2024 (Q2)	0.56 / 0.64	0.43	48.84% (+0.21)	―
May 07, 2024	2024 (Q1)	0.39 / 0.41	0.23	78.26% (+0.18)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PEN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2026	$324.19	$324.65	+0.14%
Feb 25, 2026	$339.59	$338.67	-0.27%
Nov 05, 2025	$225.54	$264.61	+17.32%
Jul 29, 2025	$227.15	$254.21	+11.91%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Penumbra Inc. (PEN) report earnings?

Penumbra Inc. (PEN) is schdueled to report earning on Aug 04, 2026, After Close (Confirmed).

What is Penumbra Inc. (PEN) earnings time?

Penumbra Inc. (PEN) earnings time is at Aug 04, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PEN EPS forecast?

PEN EPS forecast for the fiscal quarter 2026 (Q2) is 1.16.